Medical News

RSS

Astex to present data on direct acting antiviral agents against HCV at 62nd AASLD meeting

Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics, announced that it will present data on its novel, first-in-class direct acting antiviral agents (DAA) against Hepatitis C Virus (HCV) at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, November 4-8, 2011.

31 Oct 2011

FDA approves Pacira's EXPAREL for postsurgical pain management

Pacira Pharmaceuticals, Inc. announces that the U.S. Food and Drug Administration (FDA) has approved EXPAREL 1.3% for administration into the surgical site to produce postsurgical analgesia.

31 Oct 2011

BerGenBio commences preclinical development of BGB324 anti-cancer drug

BerGenBio AS, an emerging oncology biopharma, today announced it has initiated preclinical development of its proprietary lead compound, BGB324. This compound will be a first-in-class inhibitor of AXL kinase.

31 Oct 2011

Humana third quarter consolidated revenues increase 11% to $9.30 billion

Humana Inc. today reported diluted earnings per common share (EPS) for the quarter ended September 30, 2011 (3Q11) of $2.67, compared to $2.32 per share for the quarter ended September 30, 2010.

31 Oct 2011

Fierce Vaccines highlights Inovio's VGX-3100 as one of 10 Promising Therapeutic Vaccines

Inovio Pharmaceuticals, Inc., which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that VGX-3100, its investigational SynCon vaccine for treating cervical dysplasia and cancer caused by human papillomavirus, was highlighted by Fierce Vaccines as one of 10 Promising Therapeutic Vaccines.

31 Oct 2011

Hercules Pharma granted rights to license 22nd Century's X-22 smoking cessation aid

22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, announced today that the company licensed Hercules Pharmaceuticals LLC, its wholly-owned pharmaceutical subsidiary, exclusive worldwide rights to X-22.

31 Oct 2011

HAL Allergy initiates PURETHAL Mites PHASE II study

HAL Allergy B.V. today announced that it has included the first patient in its PHASE II dose range finding study.

31 Oct 2011

EarlySense to launch contact-free patient monitoring system in Europe

EarlySense announced today that the Company will launch its contact-free patient monitoring system in Europe at MEDICA in Duesseldorf, November 16 - 20, 2011.

31 Oct 2011

NALC's national bowling event to raise money for Muscular Dystrophy Association

Thousands of members of the National Association of Letter Carriers (NALC), an organization affiliated with the AFL-CIO, will head for scores of local bowling centers across the nation on Sunday, Nov. 6.

31 Oct 2011

Mayo Clinic, Oxford BioMedica collaborate to develop gene therapy for glaucoma

Oxford BioMedica plc, the leading gene-based biopharmaceutical company, today announces that it has entered into a research and development collaboration with Mayo Clinic, Rochester (USA) to develop a novel gene therapy for the treatment of chronic glaucoma.

31 Oct 2011

Study: New verbal autopsy methods are fast, effective and inexpensive

New research by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington shows that innovative and improved methods for analyzing verbal autopsies - a method of determining individuals' causes of death in countries without a complete vital registration system - are fast, effective, and inexpensive, and could be invaluable for countries struggling to understand disease trends.

31 Oct 2011

EBD Group launches partnering360 for life science professionals

EBD Group, the leading partnering firm for the global life science industry, today announced the launch of partnering360, an online network of professionals in the life science industry. partnering360 provides members with a personalized network to the people, the events and the information necessary for partnering success.

31 Oct 2011

Asuragen introduces ARQ IS Calibrator Panels to improve BCR-ABL1 testing for CML

Asuragen, Inc. announced today that it has commercially launched the ARQ IS Calibrator Panels (RUO), intended to aid laboratories with standardization of BCR-ABL1 quantitative measurements on the International Scale.

31 Oct 2011

Study examines link between hormonal forms of contraception and sexual functioning

Today's hormonal forms of birth control are vastly different from those used by earlier generations of women, both with lower levels of hormones and with different means of delivery (not just a pill), but many of the same problems related to women's pleasure remain.

31 Oct 2011

Eye Shelter, Menicon sign SOLO-care contact lens marketing agreement

Menicon Holdings BV and Eye Shelter SA, a wholly owned subsidiary of Laboratoires Thea, a France-based independent ophthalmic group, announced on October 31 that Menicon is to become Eye Shelter's exclusive partner to market the SOLO-care (R) contact lens solutions range in member states of the European Economic Area and Canada.

31 Oct 2011

Neutralization approach appears to prevent proliferative vitreoretinopathy

Proliferative vitreoretinopathy (PVR), or the formation of scar tissue within the eye, is a serious, sight-threatening complication in patients recovering surgical repair of retinal detachment. A new study conducted by investigators at the Schepens Eye Research Institute, the Department of Ophthalmology at Harvard Medical School, and the Massachusetts Eye and Ear Infirmary in Boston, published in the December issue of the American Journal of Pathology, suggests that a cocktail containing reagents to neutralize a relatively small subset of vitreal growth factors and cytokines may be an effective treatment.

31 Oct 2011

Dramatic increase in prevalence of chronic health conditions among minority immigrants

Minority immigrants are at higher risk of experiencing poor health outcomes the longer they stay in the U.S., according to new research released today at the American Public Health Association's 139th Annual Meeting in Washington, D.C.

31 Oct 2011

Scientists identify key mechanism of tumor metastasis

Scientists at Dalhousie University in Nova Scotia have identified a key mechanism of metastasis that could lead to blocking tumor growth if their findings are confirmed.

31 Oct 2011

Study looks at the strain of military deployment on adolescent boys and girls

Adolescent boys with at least one parent in the military are at elevated risk of engaging in school-based physical fighting, carrying a weapon and joining a gang, according to research presented today at the American Public Health Association's 139th Annual Meeting in Washington, D.C.

31 Oct 2011

Construction workers may face lifetime risk of occupational injuries and illnesses

Nearly all construction workers will experience one or more work-related injuries or illnesses over a lifetime plus a greater risk of premature death, according to new data released today at the American Public Health Association's 139th Annual Meeting.

31 Oct 2011